Preoperative therapy has been shown to improve overall survival in gastrointestinal cancers, and its use is undergoing evaluation in other disease sites (1) (2) (3) . Neoadjuvant radiotherapy targets the local tumor and regional lymph nodes to reduce incomplete resection, while systemic chemotherapy helps eliminate occult distant metastases, culminating in a reduction in both local and distant recurrence. On completion of neoadjuvant therapy, patients are usually reassessed prior to surgery to ensure sufficient fitness, a desire to proceed to resection, and to exclude disease progression. The combined evaluation of neoadjuvant treatment and surgery within randomized controlled trials (RCTs) often includes assessment of overall survival, toxicity, and adverse events, supplemented by a measure of health-related quality of life (HRQL) (4, 5) . However, outcomes at the end of neoadjuvant therapy and surgery, such as treatment progression, are not often studied.
Standardized reporting of treatment progression may be important because the data can be used in practice to inform patients about what to expect when initiating neoadjuvant treatment. Specifically, this provides information regarding the likelihood of completing each phase of treatment and the subsequent impact of a failure to do so on long-term survival and HRQL. Treatment progression may also be an important prognostic indicator that can assist in shared decisions to shift the intention of treatment from curative to palliative at an early stage, to preserve remaining HRQL. A case study in oesophageal cancer surgery has highlighted inconsistency in the reporting of interface outcomes. Rates of progression through neoadjuvant treatment to surgical resection varied from 2.0% to 35.3%; however, only 26% of studies fully reported these outcomes (6) . Because these data reflect the combined success of multimodal therapy and understanding the proportions of patients not progressing through each stage of treatment informs decisionmaking, it is necessary to explore whether this reporting deficit is similar in other cancer sites, and, if confirmed, recommendations for improvement are justified.
This review was undertaken to summarize reporting standards of outcomes of neoadjuvant treatments and surgery for gastrointestinal (GI) cancer, and aimed to propose the minimum required standards for future RCTs.
Methods

Search Strategy
The OVID SP version of MEDLINE (1950 to present) and the Cochrane Central Register of Controlled Trials (Issue 12, 2011) were searched using key words for cancer, surgery, and gastrointestinal tumor sites (esophagus, stomach, colorectal liver metastases, colon, and rectum), combined using the 'AND' operator. Standard search filters for randomized trials and prospective studies were applied to ensure that phase II and III trials, both randomized and nonrandomized, were identified. Searches were limited to human studies published in English between 2009 and 2012 inclusive so as to include contemporaneous trials. Duplicate records were removed and the titles and abstracts of citations screened for eligibility by one researcher, using predetermined selection criteria. Because search filters for nonrandomized phase II studies are not well developed, the contents pages and abstracts of all issues of the three top impact factor general and surgical oncology journals (Journal of Clinical Oncology, the Journal of the National Cancer Institute, and the Annals of Surgical Oncology) were hand-searched to identify additional eligible articles.
Inclusion of Papers
Included were phase III and randomized and nonrandomized phase II trials of neoadjuvant therapy and surgery for esophageal, gastric, colon, and rectal cancer and liver resection of colorectal metastases. Phase II trials were defined as those that aimed to prospectively evaluate the safety or efficacy of treatment regimens, or explicitly contained the words 'phase II' in the title or body of the publication. Studies incorporating neoadjuvant treatments (chemotherapy, radiotherapy, or other novel biological agents) into the intervention or comparator arm were included, whereas those focusing on surgery alone were excluded. Also excluded were studies of neoadjuvant therapy before procedures other than surgery, such as endoscopic interventions or radiofrequency ablation. Papers reporting more than one cancer resection by anatomical location were excluded unless outcomes were reported separately.
Each abstract was independently read by at least one author (PC, DS, or NB), and full-text articles meeting the inclusion criteria were analyzed by three authors (NB, PC, RW, and DS). Discrepancies were resolved by discussion with JMB.
Data Extraction
Study Design and Details. The study design, tumor site, intervention and comparator, numbers of participating centers and patients, and primary endpoints were recorded for each study, as well as evidence of ethical approval. Articles were categorized as arising from a surgical or oncological department or 'both' if at least one author was affiliated with each type.
Reporting of Outcomes Relating to Treatment Progression.
To establish measures of patient flow through the stages of neoadjuvant therapy and surgery, details of the numbers and proportions of patients initiating and completing four different stages of treatment were extracted. Specifically, this included details of rates of completion of neoadjuvant treatment, progression to planned surgery, and resection rates at surgery, as well as the nature of any resections performed with both palliative and curative intent. Reporting of response to neoadjuvant treatment in resected specimens was also recorded, including the use of recognized systems for assessing tumor regression and quality assurance data, such as the number of pathologists assessing the specimens, and how reproducibly these were graded. Each outcome was categorized as fully reported, partially reported, or absent according to details documented in Table 1 . Reporting was deemed partial if some, but not all, information was provided or if there was any discrepancy in the numbers of patients within each category. Where the number of patients experiencing an outcome was zero, reporting standards were not further assessed because the other criteria for Use of a published tumor regression grading system or an unpublished system with definitions provided for each category Number of patients within each category of tumor regression * For any outcome, if all criteria were met, "full reporting" was achieved. If at least one but not all criteria were met, "partial reporting" was achieved. If no criteria were provided, reporting was deemed to be "absent. " Where the number of patients experiencing an outcome was zero, reporting standards were not further assessed because the other criteria for "full reporting" were not applicable.
'full reporting' were no longer applicable. Reporting of final histopathological tumor stage was also documented.
Data Analysis
The mean rates of noncompletion of neoadjuvant treatment, nonprogression to surgery and nonresection at planned resection were calculated, and standard deviations and ranges presented.
Results
Titles and abstracts of 9854 papers were identified, 123 full papers obtained, and 60 articles included. Two additional articles were identified from hand searching ( Figure 1 ).
Study Design and Details. The 62 articles included data from 18 phase III (7-24) and 44 phase II studies , of which 40 were nonrandomized ( Table 2 ). Tumor sites included rectum (n = 30) esophagus (n = 22), stomach (n = 8), and colorectal liver metastases (n = 2). There were more multicenter (n = 33) than single center (n = 10) studies, although 19 papers did not provide this information. The number of included patients ranged from eight to 1350, with a total of 9126 amongst all studies. The primary endpoint was reported in 16 (88.9%) and 37 (84.1%) of the phase III and II trials, respectively, and most papers (n = 54, 87.1%) reported gaining ethical approval. More than half of studies included details of surgical and oncological affiliations (n = 39, 62.9%) although this was deemed unclear in twelve articles.
Reporting of Outcomes Relating to Treatment Progression. Full and partial information concerning completion of neoadjuvant treatment was provided by 11 (17.7%) and 26 (41.9%) studies, respectively, and in another 21 (33.9%) studies these details were absent (Table 3) . Reasons for noncompletion included disease progression, treatment toxicity and patient choice.Twenty-two studies (35.5%) provided complete information regarding nonprogression to planned surgery (Table 3) , and a further nine (14.5%) reported these details incompletely. These details were absent in 19 studies (30.6%), and in 12 the completeness of reporting of this outcome was not assessed because all patients progressed from neoadjuvant treatment to surgery. Reasons for noncompletion of neoadjuvant treatment and nonprogression to surgery were similar, including disease progression, treatment toxicity, and patient choice. Nonresection at planned surgery (which was often recorded as inoperability) was reported fully and partially in six and 17 studies, respectively, and these details were absent in 21 studies (Table 4) . Commonly provided reasons for nonresection were locally advanced disease and the discovery of unsuspected metastases. Examples of operations undertaken in these patients included "open and close," bypass procedures, stoma formation, and intraoperative radiofrequency ablation. Amongst patients undergoing planned surgery, full information regarding the resections performed was provided by 13 studies (21.0%), although a further 36 (58.1%) reported this in part (Table 4) . Details regarding histopathological tumor regression were provided completely and incompletely by 14 (22.6%) and 33 (53.2%) studies, respectively (Table 5 ). Ten studies provided information regarding quality assurance of histopathological assessment. Of these, four stated that examinations were undertaken by one histopathologist (31, 39, 47, 48) , one of which blinded the pathologist to patients' clinic-pathological data (47) . Four others reported that some or all specimens underwent central review (24, 31, 65, 66) , prompting amendments to tumor regression grades amongst patients in one study (31) . One paper reported independent review of specimens by two pathologists (64) , and in another this process was used to confirm complete pathological response (67) . No study assessed intraobserver and/or interobserver reproducibility of grading of tumor regression. Final tumor stage was reported in twenty-five studies (40.3%), but in seven of these information was missing for some patients ( Table 5 ).
Summary of Outcome Data. Ranges of rates of noncompletion, nonprogression and nonresection amongst the studies providing this information were 0 to 38.5%, 0 to 43.9% and 0 to 69.2%, respectively. Means and standard deviations for each outcome are provided in Table 6 .
Discussion
This systematic review identified 18 phase III and 44 phase II studies reporting outcomes of combined neoadjuvant treatment and surgery for gastrointestinal cancer. Details of patients failing to finish neoadjuvant treatment or not progressing to surgery were completely Number of histopathologists reported 6 (9.7) 0 (0) 6 (13.6) Central review of specimens 4 (6.5) 1 (5.6) 3 (6. for patients. It is recommended that core outcomes are agreed upon and universally reported in all phase II and III studies evaluating neoadjuvant treatment and surgery, to aid decision-making and practice.
Proportions of patients successfully completing all planned stages of treatment represent surrogate endpoints because they provide information of importance to patients in the longer term (69) . While this may be true, full analysis of the association between these interface outcomes and the gold standard of overall survival is not possible using current studies because of incomplete information provided. The most marked problem was reporting of nonresection rates at planned surgery, which was fully reported in only six studies. Reasons for this observation are uncertain and have also been noted in other studies (3, 70 ). It appears that surgical studies focus on outcomes of patients undergoing completed resections, and those with inoperable disease are automatically excluded. One reason for the observation may relate to the type of clinical team running the study (ie, whether predominantly surgical or medical). It is possible that trials evaluating different sorts of neoadjuvant treatment with oncologists predominantly involved are less likely to collect this data than in studies led by surgeons. Indeed, 10 of the studies in this review did not include surgeons within the author list, whereas one study was undertaken by surgeons without oncologists. Just one of these 11 studies fully reported nonresection rates.
Within this review, reasons for incomplete treatment pathways included disease progression during neoadjuvant treatment (usually identified by repeated staging investigations), or development or exacerbations of comorbidities, often related to chemotherapy. Occasionally, patients themselves elected not to continue to resection, although reasons for this are largely unknown as few studies have investigated this cohort (71) . When surgery is planned after preoperative treatment, it is associated with the risk that it cannot be successfully completed because of locally advanced disease precluding curative resection, or the perioperative discovery of micrometastases. Both of these outcomes of "nonprogression" and "nonresection" mean treatment usually becomes palliative in intent. This is a devastating experience, and provision of information prior to surgery about this possibility is important as patients require realistic data about the chances of this occurring before treatment is initiated. If such outcomes are not routinely measured, or are if they are measured but defined in different ways, it is difficult to provide accurate and meaningful information regarding this possibility. The observed rates of nonresection in this study (reported in 23 papers) vary between 0% and 69%, which is sufficiently common that it should be routine to warn patients of this serious outcome of surgery.
Other studies have highlighted problems associated with the selection, definition and measurement of outcomes in oncological studies (72) (73) (74) . It has been suggested that progression-free survival (PFS), rather than overall survival (OS), might be a preferable primary end point (74, 75) , although whether PFS translates into OS is often questioned (76, 77) . Moreover, the use of PFS generates additional challenges because a universally recognized and accepted definition of this outcome does not currently exist (73) , although work is currently being undertaken to achieve consensus on this issue (78) . Standardization of definitions of other outcomes in surgical oncology is equally problematic, despite development of consensus guidelines in some disease sites. For example, a total of 56 definitions were identified from 97 studies reporting anastomotic leak rates following gastrointestinal surgery (79) , despite prior publication of a standard definition (80) . Additionally, a recent review of esophageal cancer surgery demonstrated that amongst 122 included studies, 10 different measures of in-hospital mortality were used, and these were defined in less than 6% of papers (81) . Similar problems exist in other disease areas such as colorectal (82) and reconstructive breast surgery (83) , resulting in challenges when comparing centers and scientifically combining data in meta-analyses. There is a particular issue with the definition and measurement of histopathological tumor regression in response to neoadjuvant treatment. A recent study found that blinded assessment of tumor regression in rectal cancer specimens was poorly reproducible amongst pathologists, and that even commonly used and validated grading systems lacked robust definitions (84) . None of the studies included in this systemic review attempted to assess this issue, however, and it therefore warrants further investigation, especially with the increasing use of preoperative chemoradiation in GI cancers.
Although this review addressed a novel and important area, it has some limitations. It was limited in time, and it is possible that standards of outcome reporting differed in preceding years, although evidence tends to support a general trend of improved reporting over time (85) . Moreover, this review did not interrogate reporting standards associated with adjuvant treatments because of difficulties associated with the comprehensive identification of studies reporting this information. Additionally, observational studies were excluded, and it is therefore possible that better quality reporting was missed. It is likely, however, that standards of outcome reporting would be worse among these nonrandomized study designs as has been demonstrated in previous reviews (3, 81) .
The problems identified in this review highlight the need for improved and consistent standards for outcome reporting in neoadjuvant surgical RCTs. This may be achieved by the development and use of "core outcome sets" (COS). A COS is a scientifically derived group of outcomes that are measured and reported as a minimum in all studies of a given disease (86) . Typically, COSs include about seven outcomes that are selected by key stakeholders who prioritise outcomes and finally agree on a core set by reaching consensus. They have been pioneered in the area of rheumatoid arthritis, where "patient reported fatigue" was added to the original COS following the introduction of patient involvement. Nonresection at planned surgery 6.5 (6.6) 0 -69.2 * These figures were calculated using reported rates of each outcome or where this could be calculated from other available data within the included studies. Rates were not included from studies where discrepancies were found with the numbers of patients in each category.
The choice of which key stakeholders to survey is not standardized but for RCTs in surgical oncology would likely include physicians, surgeons, oncologists, pathologists, nurse specialists, and patients. Core outcome sets now exist for many other rheumatological conditions, and their use is mandated by grant bodies and regulatory approvals (87) . Further similar work, in surgical settings, is being led by the Core Outcome Measurement in Effectiveness Trials (COMET) initiative (88), which aims to reduce outcome reporting bias and improve data synthesis while ensuring that outcomes are not only relevant to clinicians but also important to and reported by patients themselves. Once developed, one mechanism for disseminating and implementing the core outcome set would be to mandate reporting of these outcomes as a minimum in all studies of surgical oncology. This review demonstrates that reporting of outcomes related to treatment progression in neoadjuvant surgical RCTs is inadequate, making it difficult to synthesize results, compare centers, and inform practice. Reporting standards of these outcomes require urgent attention, and it is recommended that a core set of outcomes is developed to be measured and reported as a minimum for all studies. This will require engagement between surgeons, oncologists, pathologists, and patients, in order to ensure that the selected outcomes are relevant to all stakeholders.
